Key result
Circulating Lipoprotein(a) levels were significantly higher in patients with abdominal aortic aneurysm compared to controls (SMD 0.87; 95% CI 0.41-1.33; P < .001).
Why the study?
Are circulating Lipoprotein(a) levels significantly higher in patients with abdominal aortic aneurysm compared to controls?
Meta-Analysis
Are circulating Lipoprotein(a) levels significantly higher in patients with abdominal aortic aneurysm compared to controls?
Standardized Mean Difference: 0.87 (95% CI 0.41–1.33)
p-value: p=< .001
Circulating Lipoprotein(a) levels are significantly elevated in patients with abdominal aortic aneurysms compared to controls, suggesting its potential utility as a screening biomarker.
Elevated Lp(a) was associated with AAA presence; leaves open its value for screening or risk prediction.
Circulating markers relevant to the development of abdominal aortic aneurysm (AAA) are currently required. Lipoprotein(a), Lp(a), is considered a candidate marker associated with the presence of AAA. The present meta-analysis aimed to evaluate the association between circulating Lp(a) levels and the presence of AAA. The PubMed-based search was conducted up to April 30, 2015, to identify the studies focusing on Lp(a) levels in patients with AAA and controls. Quantitative data synthesis was performed using a random effects model, with standardized mean difference (SMD) and 95% confidence interval (CI) as summary statistics. Overall, 9 studies were identified. After a combined analysis, patients with AAA were found to have a significantly higher level of Lp(a) compared to the controls (SMD: 0.87, 95% CI: 0.41-1.33, P < .001). This result remained robust in the sensitivity analysis, and its significance was not influenced after omitting each of the included studies from the meta-analysis. The present meta-analysis confirmed a higher level of circulating Lp(a) in patients with AAA compared to controls. High Lp(a) levels can be associated with the presence of AAA, and Lp(a) may be a marker in screening for AAA. Further studies are needed to establish the clinical utility of measuring Lp(a) in the prevention and management of AAA.
No takes yet. Share an insight, caveat, or question.
Kotani et al. (2016) conducted a meta-analysis in Abdominal Aortic Aneurysm. Circulating Lipoprotein(a) levels vs. Controls was evaluated on Circulating Lp(a) levels (SMD 0.87, 95% CI 0.41-1.33, p=< .001). Circulating Lipoprotein(a) levels were significantly higher in patients with abdominal aortic aneurysm compared to controls (SMD 0.87; 95% CI 0.41-1.33; P < .001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: